Oct 5 (Reuters) – Drugmaker Insmed Inc said on
Wednesday it had bought the rights to an experimental
early-stage respiratory drug from Britain’s AstraZeneca Plc
in a deal worth $150 million.
The post UPDATE 1-AstraZeneca licenses respiratory drug to Insmed appeared first on NASDAQ.